Impella CP Demonstrates 16.3% Absolute Reduction in 10-Year Mortality in STEMI-Related Cardiogenic Shock: Long-Term Data from the DanGer Shock Trial

Sep 03, 2025 19:01 CST Updated 19:01

Johnson & Johnson

Medical Device R&D and Manufacturer

Johnson & Johnson (Abiomed)Announced in the ESC 2025 conference room its clinical study on the interventional cardiac pump Impella CP (DanGer Shock). The research results were simultaneously published in"New English"The New England Journal of Medicine (NEJM).

Research shows：

For patients with myocardial infarction complicated by cardiogenic shock, routine use of Impella CP can reduce the absolute mortality rate by 16.3% over 10 years compared to standard treatment.
As of the 10-year follow-up period, compared with the control group, the average survival time of Impella CP patients was extended by 600 days (95% CI: 235 – 966 days).

Executive Evaluation

"Long-term data from the DanGer Shock randomized controlled trial published today validated the initial findings, confirming the sustained and annually increasing survival benefits associated with the Impella CP."

---Navin Kapur Chief Medical and Scientific Officer of Cardiac Resuscitation, Johnson & Johnson Medical Technology

DanGer Shock Clinical Study byInitiated by researchers, it is a long-termRandomized Controlled Trial (RCT), This StudyInBetween 2013 and 2023, 360 participants were enrolled across 14 centers in Denmark, Germany, and the United Kingdom.After a follow-up of up to ten years, it was found that:Impella CP CollectionBenefits Increase Over TimeIncreasing year by year, acceptance after ten years of surgeryThe absolute mortality rate of Impella CP patients decreased by 16.3% compared to the control group.Improved compared to the initial 6-month data---Early studies show that routine use of Impella CP can reduce absolute mortality risk by 12.7%.

Impella CPThe first mechanical circulatory support (MCS) device proven by randomized controlled trials to provide short-term and long-term survival benefits for patients with cardiogenic shock caused by ST-segment elevation myocardial infarction (STEMI).American College of Cardiology(ACC) andAmerican Heart Association (AHA) based onDanGer Shock Clinical Data, WillImpella Guidelines Recommendation Level Upgraded to Class 2a.

Impella CP

Impella is an interventional artificial heart assist device designed, developed, and manufactured by Johnson & Johnson. The device is retrogradely inserted into the aortic valve via the femoral artery.Used for cardiogenic shock, left ventricular unloading (in combination with ECOM), high-risk PCI treatment, ventricular tachycardia ablation, and right ventricular failure treatment.

ImpellaDeveloped based on the principle of the Archimedes screw pump from ancient Greek mathematician Archimedes, the rotation of the impeller can assist in generating forward blood flow, increasing cardiac output, peripheral tissue perfusion, and coronary artery blood flow.

The main products in the Impella series include the Impella CP,Impella 5.5、Impella RP andImpella RP Flex, etc.

Impella CP

Equipped with SmartAssist intelligent assistance system, peak flow rate up to 4.3 liters/minute

Impella 5.5

Equipped with SmartAssist intelligent assistance system, with an average flow rate of 5.5 liters per minute.

Impella RP

Equipped with the SmartAssist intelligent auxiliary system, a minimally invasive right heart assist pump driven by smart technology, with a flow rate exceeding 4.0 liters per minute.

Impella RP Flex

Equipped with the SmartAssist intelligent assistance system, it uses dual-sensor technology to assist pump management, with a blood delivery flow rate exceeding 4.0 liters per minute.

Johnson & Johnson

Johnson & Johnson has always been committed to addressing the most complex health challenges globally. For a century, we have driven the advancement of surgical care through innovative products such as wound closure, hemostatic assistance, surgical stapling devices, robotics, and digital solutions. Collaborating with clinical experts worldwide, we continuously revolutionize surgical techniques to better meet patient needs in metabolic diseases, cardiovascular conditions, oncology, and reconstructive surgery.